Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY4101174 |
Synonyms | |
Therapy Description |
LY4101174 is an antibody-drug conjugate (ADC) comprising a Nectin4 antibody conjugated to the topoisomerase I inhibitor exatecan, which induces double-stranded DNA breaks and potentially inhibits tumor growth (PMID: 39440991). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY4101174 | LY 4101174|LY-4101174|ETx22|ETx-22|ETx 22 | LY4101174 is an antibody-drug conjugate (ADC) comprising a Nectin4 antibody conjugated to the topoisomerase I inhibitor exatecan, which induces double-stranded DNA breaks and potentially inhibits tumor growth (PMID: 39440991). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 1 |